NYSE •
Healthcare •
Biotechnology •
Quote as of 05/04/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNYSE
Market Capitalization472.51 mln
Float100 mln
Earnings Date05/04/2026
Piotroski F-Score
5
/ 9
Neutral
Beneish M-Score
-2.33
Borderline
Relative Strength
5
/ 100
Severely lagging
Debt / Equity
-0.63
Negative equity
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
ADC Therapeutics is a Swiss-American biotech company focused on developing targeted cancer treatments using antibody drug conjugate technology. Its leading medicine, ZYNLONTA, has received regulatory approval in the United States, Europe, and China for treating certain types of aggressive blood cancer that have returned or stopped responding to prior treatment. The company is working to expand ZYNLONTA's use into earlier stages of disease and additional cancer types, both alone and in combination with other therapies. It is also advancing a broader pipeline of experimental treatments aimed at several other cancer targets.
